Cancer Family
Genitourinary System Neoplasm
CI-CAN-00000018Explore in graph →
Non-malignant3,856 active trials61 approved drugs307 evidence items
- NCIt
- C156482
Loading cancer entity…
Loading cancer entity…
Cancer Family
CI-CAN-00000018Explore in graph →
Clinical trials
17,398 studies whose conditions map to this entity or one of its descendants. Status and phase are as posted on ClinicalTrials.gov. 50 studies per page.
| NCT | Title | Status | Phase | Enrollment (n) | Sponsor | Countries | Last update | Source |
|---|---|---|---|---|---|---|---|---|
| NCT06257693 | Enzalutamide Implants (Enolen) in Patients With Prostate Cancer | recruiting | Phase 1 | 45 | Alessa Therapeutics Inc.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06306612 | CytoREductive prostAtectomy for Poly-metastatic Hormone sensiTIVE Prostate Cancer(CREATIVE) | recruiting | N/A | 192 | RenJi HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06358469 |
| STRatIfication of Vulvar SCC by HPV and p53 Status to Guide Excision(STRIVE) |
| recruiting |
| N/A |
| 249 |
| Canadian Cancer Trials GroupNETWORK |
| 2 |
| Aug 11, 2026 |
| clinicaltrials |
| NCT06469710 | A Trial to Evaluate the Effect of Applying Leukapheresis to Enrich CTCs in mPCa Patients | recruiting | — | 50 | RenJi HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT06891209 | Exploration of HRQOL and Urinary Outcomes Following Partial Cystectomy | recruiting | — | 300 | Mayo ClinicOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07187869 | Modulation of the Bone Immune Microenvironment Following Cabozantinib Treatment of Bone Metastatic Clear Cell Renal Cell Carcinoma: Proof of Concept Study | recruiting | Phase 1 | 16 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07195682 | A First-in-Human Study of BMS-986506 in Participants With Advanced Clear Cell Renal Cell Carcinoma (ccRCC) | recruiting | Phase 1 | 281 | Bristol-Myers SquibbINDUSTRY | 5 | Aug 11, 2026 | clinicaltrials |
| NCT07239596 | Phase Ib/II Clinical Study of SHR-8068 Combined Anti-tumor Drugs in the Treatment of Advanced Renal Cell Carcinom | recruiting | Phase 1 / Phase 2 | 92 | Suzhou Suncadia Biopharmaceuticals Co., Ltd.INDUSTRY | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07336134 | PopSci CHW4CervixHealth | recruiting | N/A | 120 | Thomas Jefferson UniversityOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07615348 | CD70-Targeted Immuno-PET/CT-Directed Free of Therapy Used for mccRCC Patients With IMDC Favorable or Intermediate Risk(PERFUMER-70) | recruiting | Phase 2 | 75 | Jinling Hospital, ChinaOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT07755592 | miRNA Panel for PCa Diagnosis | recruiting | — | 500 | RenJi HospitalOTHER | 1 | Aug 11, 2026 | clinicaltrials |
| NCT00488878 | Data Collection for Patients With Low Grade Ovarian or Peritoneal Tumors | recruiting | — | 2,000 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03824652 | WALNUTS for POWER: Polyphenols, Omega-3 Fatty Acids, Weight Loss, and EneRgy | recruiting | Phase 2 | 50 | Stephen FreedlandOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT04923178 | A Multi-Center Natural History of Urothelial Cancer and Rare Genitourinary Tract Malignancies | recruiting | — | 1,100 | National Cancer Institute (NCI)NIH | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05046080 | Clinicopathologic and Ancillary Testing of Primary Clear Cell Carcinoma of the Cervix | recruiting | — | 70 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05372484 | Rice Technologies for Cervical Cancer Screening and Diagnosis | recruiting | N/A | 678 | M.D. Anderson Cancer CenterOTHER | 2 | Aug 10, 2026 | clinicaltrials |
| NCT05832086 | Intermittent Fasting Using a Fasting-Mimicking Diet to Improve Prostate Cancer Control and Metabolic Outcomes | recruiting | Phase 2 | 138 | Stephen FreedlandOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT05840484 | Comprehensive Monitoring of Men With Prostate Cancer Cared for by "Active Surveillance | recruiting | — | 100 | M.D. Anderson Cancer CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT06067841 | A Study to Assess BMS-986460 in Participants With Metastatic Castration-resistant Prostate Cancer | recruiting | Phase 1 | 140 | Bristol-Myers SquibbINDUSTRY | 3 | Aug 10, 2026 | clinicaltrials |
| NCT06549855 | PD-1 Inhibitor Combined With Progesterone Treatment in FST for Patients With MMRd Endometrial Cancer | recruiting | N/A | 10 | Peking University People's HospitalOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07336446 | A Trial to Learn How Safe AZD9750 is and How Well it Works in People With Metastatic Prostate Cancer When Given With or Without Other Anticancer Drugs(ANDROMEDA) | recruiting | Phase 1 / Phase 2 | 300 | AstraZenecaINDUSTRY | 8 | Aug 10, 2026 | clinicaltrials |
| NCT07351110 | Improving Cervical Cancer Prevention Among Women Living With Chronic Conditions.(PINPOINT) | recruiting | N/A | 20 | University of FloridaOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07415681 | GCCC 2578 Randomized Photon vs Proton RT for Newly Diagnosed Gynecologic Primaries | recruiting | Phase 2 | 116 | University of Maryland, BaltimoreOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07741968 | A Blended e-Health Intervention to Improve Fear of Progression in Women With Gynecologic or Breast Cancer | recruiting | N/A | 126 | City of Hope Medical CenterOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07754929 | E-Mergir: A Digital Psychosexual Intervention for the Promotion of Mental and Sexual Health of Prostate Cancer Survivors(E-Mergir) | recruiting | N/A | 106 | Universidade do PortoOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT07756437 | Validation of a Circulating Tumor DNA Blood Test in Muscle-Invasive Bladder and Upper Tract Urothelial Cancer(BLUT-DNA) | recruiting | — | 70 | AZ Sint-Lucas GentOTHER | 1 | Aug 10, 2026 | clinicaltrials |
| NCT03719547 | Robot-assisted Approach to Cervical Cancer(RACC) | recruiting | N/A | 800 | Karolinska InstitutetOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT04251052 | A Study to Compare Two Surgical Procedures in Individuals With BRCA1 Mutations to Assess Reduced Risk of Ovarian Cancer | recruiting | N/A | 1,956 | NRG OncologyOTHER | 3 | Aug 7, 2026 | clinicaltrials |
| NCT04291612 | Observational Study of Women With Endometrial Cancer Who Receive the Standard Treatment for Their Disease | recruiting | — | 1,715 | Memorial Sloan Kettering Cancer CenterOTHER | 5 | Aug 7, 2026 | clinicaltrials |
| NCT04752722 | LEGEND Study: EG-70 in NMIBC Patients BCG-Unresponsive and High-Risk NMIBC Incompletely Treated With BCG or BCG-Naïve | recruiting | Phase 1 / Phase 2 | 350 | enGene, Inc.INDUSTRY | 10 | Aug 7, 2026 | clinicaltrials |
| NCT06580314 | Testing Olaparib for One or Two Years, With or Without Bevacizumab, to Treat Ovarian Cancer | recruiting | Phase 3 | 880 | NRG OncologyOTHER | 3 | Aug 7, 2026 | clinicaltrials |
| NCT06751329 | A Study of DM002 in Patients With Advanced Solid Tumors | recruiting | Phase 1 / Phase 2 | 280 | Xadcera Biopharmaceutical (Suzhou) Co., Ltd.INDUSTRY | 2 | Aug 7, 2026 | clinicaltrials |
| NCT07151391 | The Use of Guarana to Treat Fatigue in Patients With Neuroendocrine Tumors and Gynecologic Cancers (Guarana Fatigue) | recruiting | Phase 2 | 86 | University of UtahOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07184957 | Prospective Database of Clinical Outcomes Following Cryotherapy for Ablation of Clinically Localized Prostate Cancer | recruiting | — | 1,000 | NYU Langone HealthOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT07753343 | Identification and Description of Patients With High-risk Non Metastatic RCC(HIROES) | recruiting | — | 6,109 | University Hospital, BordeauxOTHER | 1 | Aug 7, 2026 | clinicaltrials |
| NCT01050504 | Collecting and Studying Blood and Tissue Samples From Patients With Locally Recurrent or Metastatic Prostate or Bladder/Urothelial Cancer | recruiting | — | 1,500 | University of WashingtonOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT05610852 | Single-Port Transvesical Partial Prostatectomy Versus High Intensity Focused Ultrasound | recruiting | N/A | 276 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06145633 | Vorinostat and 177Lu-PSMA-617 for the Treatment of PSMA-Low Metastatic Castration-Resistant Prostate Cancer | recruiting | Phase 2 | 15 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06188520 | A First-in-human Dose Escalation and Expansion Study to Evaluate the Safety, and Tolerability of AZD8421 Alone or in Combination in Participants With Selected Advanced or Metastatic Solid Tumors(CYCAD-1) | recruiting | Phase 1 / Phase 2 | 564 | AstraZenecaINDUSTRY | 5 | Aug 6, 2026 | clinicaltrials |
| NCT06386887 | Fasting During Neoadjuvant Chemotherapy in Patient With Epithelial Ovarian Cancer | recruiting | N/A | 20 | Case Comprehensive Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06417190 | Bladder Preservation for Patients With Muscle Invasive Bladder Cancer (MIBC) With Variant Histology | recruiting | Phase 2 | 20 | Leslie BallasOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06907446 | Comparison of New SUREcore Biopsy of Needle to Standard of Care During Transperineal Prostate Biopsies | recruiting | N/A | 50 | University of California, DavisOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07144228 | Validation of a Platelet Proteomic Assay for Diagnosing and Monitoring Prostate Cancer | recruiting | — | 300 | Duke UniversityOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07223385 | High Cardiovascular Risk Intervention With Cardio-Oncology Consultation for Prostate Cancer Following Androgen Receptor Pathway Inhibitor (ARPI) Therapy (Heart-Safe) | recruiting | Phase 2 | 80 | Cedars-Sinai Medical CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07455903 | Assessing Efficacy of Neoadjuvant ADT in Localized High-Risk Prostate Cancer Patients Utilizing 18F-Flotufolastat PSMA PET/CT | recruiting | Phase 2 | 50 | Baptist Health South FloridaOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT07731880 | Influencing Next-Generation Oncologic Outcomes Through Rapid Integration of Functional Precision Medicine (NOORI): A Feasibility Study of SmartMatch in Rare Gynecologic Cancers | recruiting | — | 30 | Fred Hutchinson Cancer CenterOTHER | 1 | Aug 6, 2026 | clinicaltrials |
| NCT06412120 | Study Evaluating Safety, Tolerability, and Metabolism of Niraparib | recruiting | Phase 4 | 70 | University of MiamiOTHER | 2 | Aug 5, 2026 | clinicaltrials |
| NCT06809140 | Enfortumab Vedotin Plus Pembrolizumab With Selective Bladder Sparing for Treatment of Muscle-invasive Bladder Cancer | recruiting | Phase 2 | 75 | Matthew GalskyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
| NCT06910657 | IDOV-Immune for Advanced Solid Tumors | recruiting | Phase 1 | 78 | ViroMissile, Inc.INDUSTRY | 2 | Aug 5, 2026 | clinicaltrials |
| NCT07000084 | Testing the Addition of an Anti-Cancer Drug, Gemcitabine, to Usual Treatment (BCG Alone) in People Whose Non-Muscle Invasive Bladder Cancer (NMIBC) Came Back After Prior BCG Therapy(GAIN-BCG) | recruiting | Phase 3 | 330 | Alliance for Clinical Trials in OncologyOTHER | 1 | Aug 5, 2026 | clinicaltrials |
Data updated 24 days agoSource updated Aug 11, 2026source: clinicaltrials